![An S1P1 receptor agonist (EC50 = 0.047 μM for [35S]GTPγS binding to CHO-K1 cell membranes expressing the human receptor); decreases surface expression of S1P1 and increases phosphorylation of Akt and ERK in CHO cells expressing S1P1-HA at 100 nM; reduces protein levels of IFN-γ and IL-17 in spinal cord tissue and decreases disease severity in a rat model of EAE at 1.3 and 3 mg/kg; decreases peripheral counts of total lymphocytes and total](https://interpriseusa.com/wp-content/uploads/2021/06/27670.png)
Description
An S1P1 receptor agonist (EC50 = 0.047 μM for [35S]GTPγS binding to CHO-K1 cell membranes expressing the human receptor); decreases surface expression of S1P1 and increases phosphorylation of Akt and ERK in CHO cells expressing S1P1-HA at 100 nM; reduces protein levels of IFN-γ and IL-17 in spinal cord tissue and decreases disease severity in a rat model of EAE at 1.3 and 3 mg/kg; decreases peripheral counts of total lymphocytes and total, CD4+, CD8+, and CD26L+ T cells in an EAE rat model, as well as in healthy control animals, at 1.3 mg/kg
Formal name: 2-amino-2-[5-[5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-benzofuranyl]-1,3-propanediol
Synonyms:
Molecular weight: 443.9
CAS: 1220973-37-4
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity
